2025 Obesity Drug Study: What the Research Shows

With dozens of weight-loss medications now available or in development, clinicians and patients face an increasingly complex set of choices. A landmark 2025 network meta-analysis published in The BMJ offers the most comprehensive head-to-head comparison of obesity drugs to date — analyzing 262 randomized controlled trials involving nearly 100,000 participants and evaluating 19 different drugs across 24 clinical outcomes (Nong et al., 2026). The findings reveal important trade-offs between efficacy, side effects, and cardiovascular benefit that should inform shared decision-making conversations between patients and their providers.

What This Study Found

Researchers conducted a systematic review and network meta-analysis, searching Medline, Embase, and the Cochrane Library through November 2025. All included trials were randomized controlled trials of at least 12 weeks' duration, with follow-up ranging from 12 to 172 weeks. Results were graded using the GRADE framework to assess evidence certainty.

Weight Loss at One Year

Compared with lifestyle modification alone, the study found moderate-to-high certainty evidence of substantial weight loss with several agents at one year:

• Tirzepatide produced the greatest weight reduction among approved agents, with a mean body weight decrease of 14.9% (95% CI: −16.0% to −13.9%).
• CagriSema (cagrilintide-semaglutide), an investigational combination drug, showed comparable results at −14.8% (95% CI: −16.9% to −12.7%).
• Oral semaglutide demonstrated a mean reduction of −10.9% (95% CI: −12.7% to −9.1%).
• Orforglipron, an oral GLP-1 receptor agonist, showed −9.9% (95% CI: −12.4% to −7.5%).
• Subcutaneous semaglutide produced −9.8% (95% CI: −10.6% to −9.1%).
• Phentermine-topiramate resulted in −8.1% (95% CI: −9.7% to −6.5%).

Emerging agents — including ecnoglutide, mazdutide, and retatrutide — may produce weight reductions in the range of 13.1–14.6%, though the researchers noted these estimates carry very low to low certainty evidence and require further validation.

Safety and Adverse Events

Greater weight loss generally came with greater risk of side effects, the study suggests. Discontinuation due to adverse events was highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide, with risk ratios ranging from 1.9 to 4.2. Gastrointestinal events were most elevated with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios from 3.1 to 4.2).

Fatigue risk was also notably increased with certain agents. Naltrexone-bupropion showed a risk ratio of 8.9 — translating to approximately 331 additional fatigue cases per 1,000 people over one year. Orforglipron and CagriSema also increased fatigue risk (risk ratios of 3.4 and 3.2, respectively).

Body Composition

The researchers found that tirzepatide reduced fat mass the most — by approximately 25.7% — but also led to the greatest reduction in lean mass (8.3%). This loss of lean muscle alongside fat is a clinically relevant consideration, particularly for older adults or individuals concerned about long-term metabolic health and physical function.

Cardiovascular Outcomes

Subcutaneous semaglutide was the only drug associated with statistically significant reductions in all-cause mortality (risk ratio 0.81; 95% CI: 0.72 to 0.93) and myocardial infarction (0.72; 95% CI: 0.61 to 0.85), though the researchers noted these estimates were largely driven by cardiovascular outcome trials in high-risk populations. Both subcutaneous semaglutide and tirzepatide were associated with reduced heart failure risk (risk ratios of 0.43 and 0.49, respectively).

Notably, no drugs in the analysis convincingly reduced kidney failure risk or improved quality of life beyond the established minimally important difference threshold of 10 points — a finding the researchers described as significant, given that quality of life is a primary goal for many patients pursuing obesity treatment.

Clinical Significance

The scale and rigor of this analysis make it one of the most informative resources available to clinicians navigating the expanding landscape of anti-obesity medications. The study's use of both frequentist random-effects models and Bayesian dose-response models, alongside GRADE evidence grading, strengthens the reliability of its comparative conclusions.

Perhaps the most clinically important takeaway is that larger weight loss does not automatically translate into better overall outcomes. Tirzepatide, for instance, produced the greatest weight reduction but also the greatest lean mass loss and significant gastrointestinal burden. Subcutaneous semaglutide, while producing less total weight loss than tirzepatide, was the only agent with evidence supporting reduced mortality and cardiovascular events — a distinction that matters enormously for patients with established heart disease or high cardiovascular risk.

The study also highlights that longer treatment duration may amplify benefits. Subgroup analyses for subcutaneous semaglutide showed larger weight reductions in trials with longer follow-up, suggesting that sustained pharmacotherapy — rather than short-term use — may be necessary to capture the full therapeutic benefit of these agents.

The absence of meaningful quality-of-life improvement across all studied drugs is a finding that warrants further research. Despite significant reductions in body weight, patients in these trials did not consistently report improvements beyond clinically meaningful thresholds, raising questions about the psychosocial and functional components of obesity treatment that weight-focused endpoints alone may not capture.

Current Access and Compliance Context

Access to these medications remains a significant barrier for many patients. Subcutaneous semaglutide and tirzepatide — the two agents with the strongest efficacy and cardiovascular data — carry substantial list prices and face inconsistent insurance coverage across payers and health systems. Oral formulations such as oral semaglutide and the investigational orforglipron may eventually offer greater accessibility, though the study suggests these come with their own tolerability challenges, including higher rates of gastrointestinal adverse events and drug discontinuation.

Medication adherence is another critical variable. The high discontinuation rates observed across multiple agents in this analysis — particularly those with prominent gastrointestinal side effects — reflect real-world challenges that extend beyond the controlled conditions of clinical trials. Patients who discontinue treatment early are unlikely to achieve the weight reductions demonstrated in these studies, and gradual dose titration strategies are often employed in clinical practice to improve tolerability.

The emergence of oral GLP-1 receptor agonists and novel combination therapies such as CagriSema signals a rapidly evolving treatment landscape. Clinicians and patients should expect ongoing updates to treatment guidelines as long-term safety and efficacy data from real-world populations continue to accumulate.

What Patients Should Know

If you are living with overweight or obesity and considering pharmacological treatment, this study offers several important points to discuss with your healthcare provider:

• More weight loss does not always mean more benefit. The drug that produces the greatest number on the scale may not be the best fit for your individual health profile, risk factors, or lifestyle.
• Side effects are real and vary significantly. Gastrointestinal symptoms, fatigue, and treatment discontinuation are common across many of these medications. Knowing what to expect — and having a plan for managing side effects — can improve your chances of staying on therapy long enough to see meaningful results.
• Lean mass loss deserves attention. Medications that reduce both fat and muscle may require complementary strategies such as resistance exercise and adequate protein intake to preserve physical function over time.
• Cardiovascular history matters. If you have a history of heart disease or are at elevated cardiovascular risk, the evidence supporting subcutaneous semaglutide for mortality and heart attack reduction may make it a particularly relevant option to explore with your doctor.
• Quality of life is a valid treatment goal. The study found no drug meaningfully improved quality of life beyond established thresholds. This underscores the importance of combining pharmacotherapy with behavioral support, mental health resources, and lifestyle counseling as part of a comprehensive obesity care plan.
• Treatment is an ongoing conversation. The researchers emphasize shared decision-making — meaning the right choice depends on your individual goals, risk tolerance, comorbidities, and preferences. No single drug is right for every patient.

Conclusion

The 2025 BMJ network meta-analysis by Nong and colleagues represents a significant contribution to our understanding of anti-obesity pharmacotherapy. Its findings confirm that today's obesity medications can produce meaningful weight loss, but remind us that efficacy must always be weighed against tolerability, cardiovascular impact, body composition effects, and real-world quality of life. As the field continues to evolve — with new agents in late-stage development and growing long-term safety data — informed, individualized decision-making will remain essential.

If you are considering obesity treatment and want to connect with a clinician experienced in evidence-based weight management, visit peptideassociation.org/find-a-doctor to find a qualified provider near you.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented is based on published research and is not a substitute for professional medical consultation. Always speak with a qualified healthcare provider before starting, stopping, or modifying any medication or treatment plan.

---

Citation (AMA format): Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026. doi:10.1136/bmj-2026-372161. PMID: 42419792.